Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell–cell interactions by Qian Wen et al.
Wen et al. J Transl Med  (2016) 14:41 
DOI 10.1186/s12967-016-0799-7
RESEARCH
Fusion cytokine IL-2-GMCSF 
enhances anticancer immune responses 
through promoting cell–cell interactions
Qian Wen, Wenjing Xiong, Jianchun He, Shimeng Zhang, Xialin Du, Sudong Liu, Juanjuan Wang, 
Mingqian Zhou and Li Ma*
Abstract 
Background: Potent antitumor responses can be induced through cytokine immunotherapy. Interleukin (IL)-2 and 
granulocyte–macrophage colony-stimulating factor (GM-CSF) are among the most effective cytokines to induce 
tumor-specific systemic immune responses and can act synergistically. To overcome the limitations of combined use 
of these two cytokines, we have constructed an IL2-GMCSF fusion protein and characterized its antitumor effects in 
this study.
Methods: The expression of IL-2 receptor and GM-CSF receptor of cell lines were detected with quantitative real-time 
PCR. On this basis, the bioactivities of IL2-GMCSF, especially effects on DC2.4 cells were assayed. Another function of 
IL2-GMCSF—bridge two types of cells—was assessed by cell contact counting and cytotoxicity assays. The anti-tumor 
activity in vivo of IL2-GMCSF was evaluated in the melanoma model. The statistical significance among treatment 
groups were determined by One-Way ANOVA.
Results: The fusion protein IL2-GMCSF maintained the activities of IL-2 and GM-CSF, and could significantly promote 
DC2.4 cell activities, including phagocytosis, proliferation and cytokine secretion. In addition to the inherent cytokine 
activity, IL2-GMCSF bridges direct cell–cell interactions and enhances splenocyte killing efficacy against multiple 
tumor cell lines in vitro. Co-injection of IL2-GMCSF and inactivated B16F10 mouse melanoma cells induced complete 
immunoprotective responses in about 30 % of mice.
Conclusion: These results suggested that IL2-GMCSF can efficiently regulate immune responses against tumors. 
Furthermore, as the bridging effect relies on both IL-2R and GM-CSFR and promotes interactions between immune 
and tumor cells, IL2-GMCSF may be utilized as a useful tool for dissecting specific immune responses for future clinical 
applications.
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Background
One critical role of the immune system is to maintain 
host homeostasis. However, tumor cells often estab-
lish a local suppressive environment to escape immune 
surveillance through various mechanisms [1], such as 
growth repression of immune cells to impair normal 
immune responses [2], production of immunosuppres-
sive humoral factors to block cytolytic activity of effec-
tor cells [3], down-regulation of antigen/MHC complex 
expression [4], and induction of T cell dysfunction [5] 
and suppression of T cell activities [6]. Effective antigen 
presentation and subsequent induction of active T cells 
in tumor foci are essential to inhibit tumor progression, 
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Immune responses require both direct and indirect 
cell–cell contacts. The former occurs during dendritic 
cell (DC) maturation induced by activated natural killer 
(NK) cells [7], antigen presentation, and the cytolytic 
activities of cytotoxic T lymphocytes (CTL) against tar-
get cells. Direct cell–cell contact not only enhances cel-
lular activation and signal transduction, but also ensures 
the specificity of immune responses. To enhance direct 
cell–cell interactions between tumor cells and immune 
cells, various types of fusion molecules were produced 
and applied, for example, anti-tumor associated antigen 
(TAA)-antibodies fused with cytokines [8], TAA linked 
with a molecular chaperone [9], scFv-scTRAIL [10], 
OVA-gp100 [11], interleukin-2 (IL-2)-TCR [12], etc. By 
this way, cell–cell crosstalk is promoted and biological 
processes are accelerated, exerting enhanced antitumor 
effects [13]. However, few studies reported the efficacy of 
a fusion protein composed by two immune molecules.
Cytokine is promising in enhancing indirect cell–cell 
communication in immune responses [14]. Granulocyte–
macrophage colony-stimulating factor (GM-CSF) and 
IL-2 are among the most powerful cytokines to induce 
tumor-specific systemic immune responses in experi-
mental models and clinical trials [15, 16]. GM-CSF per-
forms multiple immunoregulatory activities, including 
promoting differentiation of granulocyte, macrophage, 
and eosinophil precursor cell [17], as well as stimulation 
and recruitment of DCs [18]. Meanwhile, GM-CSF also 
improves the expression of IL-2 receptors on the surface 
of T cells and is one of the most potent cytokines that 
exert long-distance antitumor effects [19]. Although IL-2 
is mainly produced by T helper cells, functional IL-2 in 
DCs is still transiently upregulated soon after encounter-
ing bacteria, which is critical for DC-mediated activa-
tion of T cells [20]. IL-2 is important in tumor exclusion 
[19] through stimulating effector cells such as CTLs, 
NK cells, and macrophages [21]. Lymphokine-activated 
killer (LAK) cells [22] and tumor-infiltrating lymphocytes 
(TILs) induced by high doses of IL-2 [23] in  vitro can 
infiltrate tumors to destroy them [24], even NK-resistant 
tumor cells [25]. Moreover, IL-2 contributes to the main-
tenance of T-cell homeostasis by promoting activation-
induced cell death of effector T cells during the late stage 
of antigen-specific T-cell responses [26].
IL-2 and GM-CSF can not only stimulate the prolifera-
tion and cytotoxicity of TILs in the presence of tumor 
cells [27] but also promote the activation and cytotoxic-
ity of monocytes to attack melanoma in vitro [28, 29] and 
prolong the survival of polymorphonuclear neutrophils 
[30]. The amount of activated immune cells in periph-
eral blood correlates with the survival rate of patients 
[31], thus the combined applications of IL-2 and GM-
CSF were regarded as a promising strategy for cancer 
immunotherapy. Shinichiro et  al. used IL-2 and GM-
CSF to culture the α-GalCer-pulsed peripheral blood 
mononuclear cells and conducted the phase I and I-II 
studies in patients with non-small cell lung cancer. The 
results showed that the treatment was safe and antitumor 
immune responses depending on NKT cell were success-
fully elicited, which prolonged median survival time [32]. 
However, the substantial difference in the half-life in vivo 
and bioactivities of the two cytokines makes the results of 
their combinatory application unpredictable [33].
To achieve predictable therapeutic effects with com-
bined use of the two potent immunocompetent cytokines, 
we constructed a IL2-GMCSF fusion cytokine [34]. Such 
a fusion cytokine has been reported to enhance anti-
tumor immune responses and NK cell activities. How-
ever, the effect of the fusion cytokine on DC activity has 
not been explored. In this study, we studied the role of this 
fusion protein in regulating DC activity, and showed that 
it functions not only keep the immune activities of both 
cytokines but also promote direct cell–cell interactions 
through acting as a bridge to bring different types of cells 
in close proximity by direct binding with their cytokine 
receptors respectively which will improve intercellular 
communications and in turn enhance immune responses.
Methods
Animals and cells
The 6-8-week-old male BALB/c mice, C57BL/6 and 
5-week-old male nude mice were provided by the Center 
for Laboratory Animal Sciences of Southern Medical Uni-
versity (Guangzhou, China). FDC-P1 cells (ATCC CRL-
12103) and WEHI-3 cells (ATCC TIB-68) (Peking Union 
Medical University, Beijing, China) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM. Hyclone 
Ltd, Logan, UT) containing 10 % fetal bovine serum (FBS. 
Hyclone). For culture of FDC-P1 cells, 10  % of WEHI-3 
cell-conditioned medium (WEHI-3/CM) was supple-
mented. CTLL-2 cells (ATCC TIB-214), murine A1.1 T 
cell hybridoma [35] (kindly gift from Dr. Yufang Shi, The 
Key Laboratory of Stem Cell Biology, Institute of Health 
Sciences, Shanghai, China), B16F10 cells (ATCC CRL-
6475), B16-GMCSF (B16F10 cells stably transfected with 
mouse gm-csf gene), DC2.4 and RAW264.7 cells were 
conserved in our laboratory and maintained in RPMI-
1640 medium (Hyclone) supplemented with 10 % FBS. All 
of the five cell lines were derived from C57BL/6 mouse.
RNA isolation and real‑time quantitative RT‑PCR
To detect the expression of IL-2 receptor and GM-CSF 
receptor, total RNA was extracted using Trizol (Life tech-
nologies, Carlsbad, CA) and reversely transcribed using the 
RevertAid First Strand cDNA Synthesis Kit (Fermentas, 
Life Sciences, Ontario, Canada) after DNase I (Fermentas) 
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treatment. The sequence of primers used were as below: 
for mIL-2Rα, FP: 5′-GCAACTCCCATGACAAATCG-3′, 
RP: 5′-CCCGGAATACACTCGTAGTGAA-3′; for mGM-
CSFRα, FP: 5′-CGTGCATATCCCCACCGTAATA-3′, 
RP: 5′-TGAAGGCACGTTGGATTTTATGA-3′; for 
GAPDH, FP: 5′-GCACGGTCAAGGCTGAGAAC-3′, 
RP: 5′-GCCTTCTCCATGGTGGTGAA-3′. Real-time 
quantitative PCR (qRT-PCR) were performed using the 
iQ™ SYBR® Green Supermix kit (Bio-Rad, Hercules, CA) 
on Mastercycler ep realplex4 (Eppendorf, Hamburg, Ger-
many). Target mRNA quantification was analyzed using 
the comparative threshold cycle (Ct) method with the soft-
ware realplex 2.2 (Eppendorf) as described previously [36].
Cell proliferation assays
Fusion protein IL2-GMCSF was prepared [34] and 
conserved in our lab. For detection the activity of IL2-
GMCSF, CTLL-2 cells or FDC-P1 cells were cultured in 
the 96-well microplate (Nunc, Thermo Fisher Scientific, 
Waltham, MA) with serially diluted IL2-GMCSF for 48 h 
(for IL-2) or 96 h (for GM-CSF). The cell viabilities were 
detected using the Cell Counting Kit-8 (CCK-8, Dojindo 
Laboratorise, Tokyo, Japan) according to the manufactur-
er’s instruction and compared with the standard curves 
prepared by cells cultured with serially diluted IL-2 or 
GM-CSF (both from PeproTech Inc., Rocky Hill, NJ).
Flow cytometry assay
After incubation with or without IL2-GMCSF (2.5 × 103 
IU/mL in terms of the activity of GM-CSF in the fusion 
protein) at 37 °C for 1 h, A1.1, DC2.4 and WEHI-3 cells 
were stained with His·Tag® mAb (Novagen, EMD Bio-
sciences, Inc., Darmstadt, Germany) at 37 °C for 1 h and 
FITC-conjugated rabbit anti-mouse IgG (Jackson Immu-
noResearch Laboratories Inc., West Grove, PA) at 4  °C 
for 30 min in turn. And the fluorescence was analyzed by 
flow cytometry. For analyzing maturation of DC2.4 cells, 
the following anti-mouse antibodies were used: anti-
CD80-FITC, anti-CD86-APC, anti-CD83-PE, anti-MHC 
class II (I-A/I-E)-PE-Cyanine7. All these fluorescent anti-
bodies and corresponding isotype antibodies were from 
eBioscience Inc. San Diego, CA.
To assay the phagocytosis ability of DC2.4 cells, cells 
with different treatments as indicated in the legends 
(2  ×  105 cells/well) were incubated in triplicate with 
1  mg/mL of fluorescein isothiocyanate-dextran (FD40, 
molecular weight 40,000, approx. 45 Angstroms, Sigma) 
at 37 °C for 15 min. After washes with PBS, the mean flu-
orescence intensity (MFI) was assayed by flow cytometry.
DC maturation and activation
B16F10 cells were seeded at the density of 106/mL in 
6-well plates (NEST Biotechnology Co.LTD., Wuxi, 
China) for 24  h. The supernatant was collected follow-
ing centrifugation to remove cell debris and used as the 
tumor cell conditioned medium (TCM). IL2-GMCSF or 
different cytokines was added in the culture of DC2.4 
cells incubated with the B16F10 TCM. Cell phagocytosis 
was assayed 24 h later, and DC proliferation and mature 
phenotype was assayed 48 h later by flow cytometry.
In vitro cytotoxicity assays
Cytotoxicity assays were carried out using a DELFIA 
EuTDA cytotoxicity kit (Perkin-Elmer Life Sciences, 
Norwalk, CT, USA) according to the manufacturers’ 
instruction. Eu-labeled other target cells (5 ×  103) were 
co-cultured with DC-CIKs at the indicated E:T ratio in 
the legend. The signals were collected using the Varios-
kan Flash reader (Thermo Fisher) and the specific lysis 
was calculated using the following formula: [(experi-
mental release − spontaneous release)/(maximum 
release  −  spontaneous release)]  ×100, where the tar-
get cells incubated alone indicated the maximum or the 
spontaneous release with or without complete cytolysis, 
respectively.
ELISA
DC2.4 cells (106/well) in 6-well plates were cultured over-
night, and then incubated with the different cytokines. 
The culture supernatant was collected 24  h later to 
detect the secretion of IL-12 and macrophage-derived 
chemokine (MDC/CCL22) with the corresponding 
ELISA kits (BOSTER Bioengineering Co. Ltd., Wuhan, 
China) as per the instructions of the manufacture. The 
absorbance was read using the Varioskan Flash reader.
Western blot analysis
After treatment as indicated in the legends, total cell 
protein was extracted using RIPA buffer (ShangHai Bio-
color BioScience Technology Company, Shanghai, China) 
containing 1/10 volumn of PhosSTOP Phosphatase 
inhibitor Cocktail (Roche), and Western blot analysis 
was performed as previously described [37]. The fol-
lowing primary antibodies were used with 1:2000 dilu-
tion: phosphorylated-NF-κB p65 (p-p65; Ser536; 93H1), 
NF-κB p65 (D14E12) XP® (Cell Signaling Technology, 
Inc., Beverly, MA), and GAPDH (Zhongshan Golden-
bridge Biotechnology Co., Ltd. Beijing, China). Immu-
nocomplexes on PVDF membrane were detected with 
appropriate horseradish peroxidase–conjugated second-
ary antibodies (1:2000; Zhongshan Goldenbridge). The 
membranes were developed with the SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific) 
according to manufacturer’s instructions and the pictures 
were collected using GeneGnome5 (Gene Company, Ltd. 
Hong Kong, China).
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Combination assays
Two types of cells (5 × 105/type) were labeled with Cell-
Tracker™ Red or CellTracker™ Green (Life technologies), 
respectively, and then gently mixed together in 100 μL of 
PBS supplemented with serially diluted fusion protein or 
medium as well as FBS (100 μL/tube). Anti-human ovar-
ian carcinoma/anti-human CD3 bispecific single chain 
fusion antibody (BHL-I) (preserved in our lab) was used 
as the unassociated control. In competition experiments, 
serially diluted GM-CSF or IL-2 was mixed with IL2-
GMCSF and coincubated with cells as indicated in the 
legends. The mixed suspensions were incubated at 37 °C 
for 10 min and then centrifuged at RT, 600 rpm for 5 min. 
After removing about 200 μL/tube of the supernatant, 
the cells were incubated at 4  °C for 2–4  h. Cell combi-
nation was observed under a microscope and cell clus-
ters including no less than three cells were counted. The 
counting was performed by two different observers who 
were blind to treatment groups.
In vivo therapy with IL2‑GMCSF
The IL2-GMCSF therapy regimen was designed accord-
ing to previous study [38] with some modification and 
approved by the Animal Ethics Committee at Southern 
Medical University. Two kinds of animal models were 
established, on C57BL/6 mice and nude mice, respec-
tively. Both of two kinds of animals were randomly 
assigned to three treatment groups (n  =  6 per group). 
To establish the melanoma model, all C57BL/6 mice 
received the injection of 5 ×  103 B16F10 cells in 50 μL 
of PBS subcutaneously on day 0, while nude mice were 
received the injection of 3 ×  107 B16F10 cells in 50 μL 
of PBS subcutaneously into both the right and left back 
flank. The immune therapy was begun on day 3. For 
preparation of tumor vaccines, on the day of vaccine 
administration, 1  ×  105 B16F10 cells were inactivated 
by incubation with 50  μg/mL mitomycin C at 37  °C for 
30  min. The inactivated tumor cells were then coincu-
bated with 2.5 × 103 IU/mL of IL2-GMCSF (in terms of 
the activity of GM-CSF. Named as BF group), combina-
tion of IL-2 and GM-CSF (named as 2CK group) or PBS 
(named as PBS group) at 37 °C for 40 min, each in a col-
umn of 50 μL. The above vaccines were subcutaneously 
injected just around the tumors on the right side while all 
the left side tumors were injected with PBS as controls. 
To enhance the immune effects, half dose of the tumor 
vaccines were administered on day 6 and 12. For thera-
peutic study, the same treatments were carried out after 
solid tumor was visible. Similar prime-boost strategy was 
carried out on day 6 and 12 after the first administration 
of tumor vaccine. Tumor volumes and animal survival 
were monitored over time.
Statistical analysis
Data from the cellular experiments are expressed as the 
mean  ±  SD. One-Way ANOVA was applied to analyze 
the statistical significance. Post hoc multiple compari-
sons were performed using least Significant Difference 
or Dunnett’s T3 methods. Statistical analysis of survival 
data from animal experiments was performed using the 
Life Tables method. The difference was considered to be 
statistically significant when P is below 0.05. All statisti-
cal analyses were performed using SPSS statistical soft-
ware version 16.0 (SPSS, Chicago, IL, USA).
Results
Gene expression assessment of receptors for IL‑2 
and GM‑CSF
The functional mediator of cytokines is their receptors 
mainly expressing on the cell surface. To explore the role 
of IL2-GMCSF in the cell interaction, we firstly evaluated 
the expression of the IL-2 receptor (IL-2R) and the GM-
CSF receptor (GM-CSFR) in different cells using qRT-
PCR, including C57BL/6 mouse splenocytes, melanoma 
cell lines B16F10 and B16-GMCSF, an immature DC cell 
line DC2.4 [39], a T cell hybridoma A1.1, a macrophage 
cell line RAW264.7 and a myelomonocytic leukemia cell 
line WEHI-3. Murine splenocytes and DC2.4 cells were 
used as the positive controls for IL-2Rα and GM-CSFRα 
expression, respectively. The results showed that A1.1 
cells only expressed IL-2R while DC2.4 cells only 
expressed GM-CSFR. In contrast, Con A-treated sple-
nocytes expressed both cytokine receptors, consistent 
with their heterogeneity and indicating the co-existence 
of lymphocytes and antigen-presenting cells (APCs) such 
as DCs and macrophages. Unexpectedly, many tumor cell 
lines, including B16F10, B16-GMCSF and RAW264.7, 
also expressed both of the two cytokine receptors, just in 
different levels. By contrast, WEHI-3 cells expressed both 
receptors in very low levels (Fig. 1a, b).
Bifunctional activity assessment of IL2‑GMCSF
To ensure the fusion cytokine has both IL-2 and GM-
CSF activities, the viability of CTLL-2 and FDC-P1 in the 
presence of serially-diluted IL2-GMCSF was assessed. 
Results of the WST-8 colorimetric method indicated that 
the fusion cytokine exerted growth promotion effects on 
IL-2-dependent splenocytes and GM-CSF-dependent 
FDC-P1 cells in a dose-dependent manner, which were 
parallel with both the IL-2 and the GM-CSF standards 
(Fig. 1c, left and middle panels). The specific activities of 
this fusion cytokine were 3.6 ×  106 IU/mg for IL-2 and 
1.1  ×  107 IU/mg for GM-CSF respectively, consistent 
with the results in our previous study [34] (Fig. 1c, right 
panel). The above assays confirmed this fusion cytokine 
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possessed both of the biological activities of IL-2 and 
GM-CSF. For convenience of description, the amount of 
IL2-GMCSF used in subsequent experiments was cal-
culated in terms of the activity of GM-CSF part of this 
fusion protein.
Subsequently, the binding of IL2-GMCSF with their 
receptors were examined on IL-2R+ A1.1 cells and GM-
CSFR+ DC2.4 cells, while IL-2RlowGM-CSFRlow WEHI-3 
cells were used as the negative control. Indirect immuno-
fluorescence staining indicated that IL2-GMCSF signifi-
cantly enhances the fluorescence-positive ratio both for 
A1.1 cells and DC2.4 cells (P < 0.05). Consistent with the 
rare expression of both IL-2 and GM-CSF receptors, the 
binding activity of IL2-GMCSF to the surface of WEHI-3 
cells was at a very low level (Fig. 1d).
Enhancement of DC2.4 cell activities enhanced 
by IL2‑GMCSF
GM-CSF has been proven to promote the phagocytic 
capacity of DCs. In this study, the effects of IL2-GMCSF 
on the phagocytotic activity of the immature DC2.4 cells 
were examined by assessing the engulfment of FD40 
Fig. 1 Identification of cell receptor expression and assays of the IL2-GMCSF bioactivity. a–b qRT-PCR was used to detect the IL-2Rα and GM-CSFRα 
chain expression in different cell lines; c IL2-GMCSF harbored the activities of its component cytokines, as demonstrated by cell proliferation assays 
of mouse splenocytes for IL-2 acivity and FDC-P1 cells for GM-CSF activity; d flow cytometry assays showed that IL2-GMCSF could bind on A1.1 
cells (IL-2R+) and DC2.4 cells (GM-CSFR+), but almost not on WEHI-3 cells which was used as the IL-2R−GM-CSFR− control. These experiments were 
repeated at least three times with similar results
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(FITC-labeled 40-kDa dextran) after incubation of cells 
with IL2-GMCSF 24  h later. Results detected by flow 
cytometry indicated that IL2-GMCSF enhanced the 
engulfment of FD40 by DC2.4 cells in a dose-depend-
ent manner. The peak level of phagocytosis appeared 
at 9.9 × 103 IU/mL, which was similar with the level at 
2.5 ×  103 IU/mL of IL2-GMCSF (in terms of the activ-
ity of GM-CSF) (P < 0.05) (Fig. 2a, upper). Further assays 
showed that this pro-phagocytic effect at 2.5 ×  103 IU/
mL of IL2-GMCSF was comparable to that of GM-CSF 
alone also at 2.5 × 103 IU/mL (Fig. 2a, lower). To make 
sure whether the synergistic effect of the two cytokines 
exists, the effects of IL-2 alone at 820  IU/mL which is 
corresponding to the IL-2 activity in IL2-GMCSF and 
the combination of the two component cytokines at 
the concentrations comparable with IL2-GMCSF were 
also compared. The results showed that IL-2 alone has 
little effect on the engulfing efficiency of DC2.4 cells. 
Consistently, the phagocytic efficacy resulting from the 
combined using of IL-2 and GM-CSF was similar to the 
fusion cytokine or GM-CSF alone (Fig. 2a, lower). These 
results indicated that IL2-GMCSF significantly enhances 
the phagocytosis of DCs, which mainly originated from 
the GM-CSF activity of the fusion protein.
Besides phagocytosis, GM-CSF has also been demon-
strated to improve DC proliferation. As results of cell 
counting 48  h after incubation showed, IL2-GMCSF 
enhanced the proliferation of DC 2.4 cells, but in a 
reverse dose-dependent manner. The peak level of pro-
liferation was observed at 1.25 × 103 IU/mL, which was 
comparable with that at 2.5 × 103 IU/mL (Fig. 2b, upper). 
Like observed in phagocytosis assays, effects of 2.5 × 103 
IU/mL of IL2-GMCSF on the proliferation of DC 2.4 cells 
were similar with that of GM-CSF alone (Fig. 2b, lower). 
And the effects seemed not to involve the activity of IL-2, 
because IL-2 alone could not promote cell proliferation, 
and the proliferative effects of IL-2 and GM-CSF com-
bination were comparable with that of GM-CSF alone, 
although lower than that of IL2-GMCSF (Fig. 2b, lower). 
Considering the opposite effects of IL2-GMCSF on DC 
proliferation and phagocytosis, we chose the IL2-GMCSF 
dose at 2.5 × 103 IU/mL for further study, which exerts 
nearly most excellent promotion on both of the activities 
of DCs.
To explore the effects of IL2-GMCSF on DC matu-
ration, the phenotype of DC2.4 cells treated with 
IL2-GMCSF were evaluated and compared with indi-
vidual cytokine treatment. FACS assays showed that 
IL2-GMCSF exerted no significant effects on DC2.4 mat-
uration as indicated by similar ratios of CD80+CD86+ 
cells and MHC-II+CD83+ cells, which is consistent 
with the enhancement on phagocytosis of DC2.4 cells 
by IL2-GMCSF. It was noteworthy that GM-CSF alone 
significantly inhibited DC maturation. Although IL-2 
alone could not affect DC cell activities as well as matura-
tion, it could counteract the effect of GM-CSF, no mat-
ter used combined or fused with GM-CSF because the 
level of DC maturation stimulated by IL2-GMCSF was 
similar with that by combined using of IL-2 and GM-CSF 
(Fig. 2c, d). Albeit the remarkable difference in DC matu-
ration between IL2-GMCSF and GM-CSF, their capac-
ity in induction of IL-12 secretion was similar (Fig.  2e). 
In contrast, significantly higher level of MDC secretion 
induced by IL2-GMCSF than GM-CSF’s performance 
(P < 0.05) was observed (Fig. 2f ).
Previously, it has been reported that NF-κB pathway 
play key roles in activation of DCs [40]. Consistent with 
above effects in stimulation of DC2.4 cells by IL2-GMCSF 
and GM-CSF alone, western blotting assays showed that 
IL2-GMCSF could also activate NF-κB signaling pathway 
as indicated by phosphorylation of p65 unit (Fig. 2g).
Enhancement of cell–cell interactions of receptor‑positive 
cells by IL2‑GMCSF
As IL-2R and/or GM-CSFR are widely expressed among 
immune cells and tumor cells, we supposed that IL2-
GMCSF should be capable of enhancing cell–cell inter-
actions by binding to both receptors and bridging them 
into close proximity. To test this hypothesis, different 
types of equal number cells were incubated in pairs with 
various concentrations of IL2-GMCSF, and individual 
cell types of coincubated cells are easy to be distin-
guished under the fluorescence microscope by staining 
with CellTracker™ Red or CellTracker™ Green respec-
tively. Fusion protein-induced cell–cell interactions were 
quantified by counting cell contacts between different 
cell types. To avoid overestimate the contact number of 
large cell clusters, which contains more than 10 cells of 
different cell types and one cell in it may possess multiple 
contacts with different cells (Fig. 3a), the contacts in such 
large cell cluster were set as 10. The results showed that 
the presence of IL2-GMCSF could drastically promote 
the formation of cell clusters and get higher number of 
contact count which is when compared with the control 
group in which IL2-GMCSF was replaced by the non-
specific fusion antibody. And this enhancement of cell–
cell interactions is in a dose-dependent manner (Fig. 3b). 
The most significant increase of cell contact numbers 
appeared in DC2.4-involved cell–cell interactions, no 
matter the co-incubated cells were tumor cells or sple-
nocytes. Relative weak effects were observed in the inter-
actions between splenocytes and tumor cells (Fig.  3b, 
lower panel, left). In addition, the presence of 2.5 × 103 
IU/mL of IL2-GMCSF also significantly promoted the 
interactions among splenocytes, indicating consistent 
results with qRT-PCR that there were IL-2R positive 
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lymphocytes and GM-CSFR positive APCs in this mixed 
cell population (Fig. 3b, lower panel, middle). To demon-
strate that the cell contact was mediated by IL2-GMCSF, 
besides the above non-specific fusion antibody, serially 
diluted GM-CSF or IL-2 corresponding with the dose of 
IL2-GMCSF was also added in the coincubation of DC2.4 
cells and B16F10 cells, to compete with the combination 
of the fusion protein and the receptor on the cell surface. 
The counting results indicated that either GM-CSF or 
IL-2 could prevent cell cluster formation (Fig. 3b, lower 
panel, right). In short, these observations demonstrated 
that IL2-GMCSF can bring different types of IL-2R and 
GM-CSFR-expressing cells into close proximity, espe-
cially interactions involving DCs.
Enhancement of in vitro cytotoxicity against tumor cells 
by IL2‑GMCSF
To test the effect of IL2-GMCSF in splenocyte cytotox-
icity against tumor cells, B16F10 cells were firstly used 
as the target cell to evaluate the effects of IL2-GMCSF 
Fig. 2 Effects of IL2-GMCSF on DC 2.4 cell bioactivities. a FD40 engulfment and b cell proliferation of DC2.4 cells under different dosage of IL2-
GMCSF or cytokines; c–d maturation of DC 2.4 cells with different cytokine treatments were indicated by expression of CD80/CD86 (e) and MHC-II/
CD83 (f) detected by flow cytometry. e IL-12 and (F) MDC secretion by DC 2.4 cells treated with IL2-GMCSF or GM-CSF were assayed with ELISA. g 
Western blotting was used to detect the activation of NF-κB p65 subunit in DC2.4 cells treated as above. In comparison of the effects of IL2-GMCSF 
and the cytokines alone or in combination, IL-2 was used at 820 IU/mL and GM-CSF at 2.5 × 103 IU/mL, corresponding to the activity of the two 
parts of the fusion protein at 2.5 × 103 IU/mL. blk: blank; BF: IL2-GMCSF fusion protein; 2CK: the combination of GM-CSF and IL-2. *P < 0.05 com-
pared with the control without cytokine treatment. These experiments were repeated at least three times with similar results
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dosages and the ratio of effector cells to target cells (E:T 
ratio). Cytotoxicity was determined by detecting cell 
viability of adherent cells remained after 48  h incuba-
tion with suspended effector cells. WST-8 assays showed 
that, in the presence of 2.5 × 103 IU/mL of IL2-GMCSF, 
the optimum E:T ratio was 20:1. The cytotoxicity against 
B16F10 cells at this ratio was significantly higher than 
at 10:1 or 5:1 (P  <  0.05), but was comparable to that at 
40:1 (P > 0.05) (Fig. 4a). This E:T ratio was then used in 
the subsequent cytotoxicity assays. Meanwhile, the sple-
nocytes effectively killed B16F10 cells in an IL2-GMCSF 
dose-dependent manner at this E:T ratio (Fig. 4b).
Considering the differences in cell characteristics and 
possibly consequent IL2-GMCSF effects, two concentra-
tions showing significant differences in the cytotoxicity 
assay against B16F10 cells were applied to other tumor 
cells (Fig. 4C). Although the dose-dependent manner of 
IL2-GMCSF in promoting cytotoxicity was not so sig-
nificant (P > 0.05 compared between different doses) as 
observed in the assay against B16F10 cells, the fusion 
cytokine significantly promoted cytotoxicity com-
pared with IL-2, GM-CSF or the cytokine combination 
(P  <  0.05) (Fig.  4d–f). Stimulation effects of single or 
combined cytokines varied greatly with their types and 
concentrations as well as cell types. For example, the 
cytotoxicity of the splenocytes was not significantly pro-
moted by the higher concentration of GM-CSF or com-
bined cytokines, and even inhibited in the presence of 
820  IU/mL of IL-2 (Fig.  4c, d). Therefore, IL2-GMCSF 
greatly enhanced the anti-tumor effects of splenocytes 
Fig. 3 IL2-GMCSF can bring cells into close proximity effectively. Such effects were as demonstrated by the cell cluster counting of several pairs 
of cell lines incubated with different concentrations of IL2-GMCSF or BHL-I. a Typical cell–cell contact (left) and separate cells (right) were shown 
by fluorescence microscopy observation after incubation of two types of cells stained with CellTracker™ Red or CellTracker™ Green respectively; b 
tumor cell lines including A1.1, B16F10, B16-GMCSF and RAW264.7 were incubated with DC2.4 cells (upper panel) or splenocytes (middle panel) 
in the presence different concentrations of IL2-GMCSF. Results of cell binding between DC2.4 cells and splenocytes (lower panel, left) and among 
splenocytes (lower panel, middle) were also shown. GM-CSF and IL-2 were used in the competition experiments to demonstrate the specific com-
bination of IL2-GMCSF with cells (lower panel, right). The representative result of three repeat experiments with similar results was shown. *P < 0.05 
compared with the control without IL2-GMCSF
Page 9 of 13Wen et al. J Transl Med  (2016) 14:41 
compared to either IL-2/GM-CSF alone or their 
combination.
Enhancements of in vivo killing efficacy against melanoma 
by IL2‑GMCSF
To evaluate whether IL2-GMCSF could also efficiently 
function against tumor in vivo, B16F10 melanoma which 
is a refractory and common cancer was used. Animals 
were inoculated subcutaneously with B16F10 cells and 
treated with tumor cell vaccines 3 days later. The tumor 
cell vaccines were composed of mitomycin C-inactivated 
B16F10 cells incubated with IL2-GMCSF (BF group), the 
above two individual cytokines (2CK group) or without 
any cytokines (PBS group).
In C57BL/6 mice, apparent tumor formation was 
observed in all groups about 20  days after inoculation 
with B16F10 cells. Although the disease initiation was 
similar among these three groups, the development of 
disease was greatly different. The tumor formation was 
observed quickly in all mice in PBS group, while until 
55  days after inoculation was observed in all mice in 
the 2CK group. In contrast, at the end of observation 
period, there were still tumor-free mice in the BF group, 
indicating the complete protection effects (i.e. no tumor 
formation after inoculation). Meanwhile, the BF group 
significantly prolonged the survival time compared with 
the 2CK group and the PBS group (P < 0.05) (Fig. 5a–c).
In nude mice, also about 20 days after tumor cell inoc-
ulation, tumor formation could be observed in most of 
groups except the BF group, in which the disease initia-
tion had been delayed for about 5  days. The tumor for-
mation in both the BF group and the 2CK group was 
significantly later than in the PBS group (P < 0.05). The 
most remarkable protective responses were observed in 
Fig. 4 IL2-GMCSF enhanced cytotoxicity in vitro. Cytotoxicity was measured using the WST-8 method to detect the viability of remained target 
cells. a–b Effects of E:T ratio of splenoctyes and B16F10 cells (a) and IL2-GMCSF dosages (b) were determined firstly. Accordingly, cytotoxicity of 
splenocytes against B16F10 cells (c), B16F10-GMCSF (d), RAW264.7 (e) and A1.1 (f) at the 20:1 E:T ratio in the presence of various IL2-GMCSF dosages 
demonstrated the promotion in cytotoxicity by IL2-GMCSF. *P < 0.05 compared with the control without any cytokine. These experiments were 
repeated at least three times with similar results
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the BF group (P < 0.05) among which 32.6 % of treated 
animals were completely protected. Similarly, the BF 
group also prolonged the survival time of nude mice sig-
nificantly (P < 0.05) (Fig. 5d, e).
Above assays were designed and performed to detect 
the prophylactic function of IL2-GMCSF. In order to 
demonstrate its therapeutic function, the same tumor 
vaccines were used to treat the visible solid tumor 
(about 8  days after inoculation of tumor cells). Nota-
bly, decrease in tumor volume was observed in both the 
BF group and the 2CK group, and the most significant 
regression appeared in the BF group (Fig. 5f, g). Together, 
IL2-GMCSF fusion protein displayed strong anti-tumor 
effects in melanoma animal model.
Discussion
The immune system functions against tumor progres-
sion with complicated mechanisms, which involve cell–
cell interactions either through direct contact or indirect 
communication by cytokines. In this study, we firstly 
examined the effects of the fusion cytokine IL2-GMCSF 
on DC 2.4 cell activities in normal and immune-inhibi-
tive conditions, and then demonstrated that IL2-GMCSF 
acts as a molecular linker which can enhance cell–cell 
interactions to promote antitumor effects. When func-
tioning as the molecular linker, IL2-GMCSF could play 
different roles in various conditions. On one hand, IL2-
GMCSF can act as an immune enhancer by bringing DCs 
and other cells in close proximity to enhance the antigen-
capturing and presentation efficiency when bound to 
tumor cells or bound to effector cells, respectively. On 
the other hand, IL2-GMCSF can also act as a cytotoxic 
enhancer by pulling effector T cells and tumor cells close 
to promote specific immune killing.
Two observations may explain the basis of IL2-GMCSF 
efficacy. First, cellular expression of IL-2R and GM-CSFR 
widely exist respectively as demonstrated in this study. In 
particular, almost all tumor cells detected in this study 
express both the IL-2 and/or GM-CSF receptors. Sec-
ond, the fusion cytokine retains the activities of both 
cytokines, including binding to its receptors on cell sur-
face, promoting proliferation of growth factor-dependent 
cells and enhancing DC activities such as phagocytosis, 
proliferation and cytokine secretion. DCs are central to 
immune function, as they participate in the initiation of 
both innate and adaptive immunity [41] as well as regula-
tory T cell differentiation [42]. Low number or impaired 
maturation of DCs will result in greatly compromised 
antitumor responses [31]. The vital role of DCs in 
immune responses demonstrates the importance of GM-
CSF in immune responses. However, in this study, the 
results showed that GM-CSF alone inhibited DC matura-
tion. Unexpectedly, the existence of IL-2 could counter-
act the effect of GM-CSF, no matter used singly or fused 
with GM-CSF. Because no IL-2 receptor was detected in 
DC2.4 cells, the mechanism of the counteraction is still 
unknown. The DC cell line used in this study, DC2.4, rep-
resents immature DCs [39] that can develop to mature 
state after antigen capture and present antigens to effec-
tor T cells. Generally, DC2.4 cells are thought to possess 
the immune activities of natural DCs in vivo.
MDC is a strong chemokine secreted by DCs and 
macrophages. MDC can recruit large amount of DCs to 
induce strong anti-tumor immune response. Cao et  al. 
transfected MDC gene into mice and found that, MDC 
could attract DCs to the tumor loci through inducing 
IL-4 secretion. Strong antigen-specific immune responses 
followed, accompanied with obvious repression of tumor 
[43]. In this study, IL2-GMCSF was demonstrated to 
own the activity to induce high levels of MDC secretion 
by immature or mature DC2.4 cells. It was noteworthy 
that such enhancement in T cell activator IL-12 was also 
observed, suggesting that IL2-GMCSF could improve the 
function of DCs in various aspects. Western blot assays 
Fig. 5 Antitumor activity of IL2-GMCSF in vivo. The percent of 
tumor-free mice (a), surviving mice (b) at different time points after 
treatment of C57BL/6 mice was assessed. The tumor was observed in 
the C57BL/6 mouse melanoma model after treatment with tumor cell 
vaccines or PBS (c). Furthermore, the percent of tumor-free mice (d), 
surviving mice (e) and the tumor volume (f) at different time points 
after treatment of nude mice was assessed. The tumor was observed 
in the nude mouse melanoma model after treatment (g). These 
experiments were repeated three times with similar results. *P < 0.05 
compared with the PBS control group
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showed enhanced activation of NF-κB signaling pathway 
in DC2.4 cells treated with IL2-GMCSF under both nor-
mal, indicating the higher level of activation of DCs by 
IL2-GMCSF.
As a mixed cell population, splenocytes contain cer-
tain amount of APCs, as shown by the expression of 
GM-CSFR and self-binding promotion by IL2-GMCSF. 
The promotion of cell–cell interaction by IL2-GMCSF 
was stronger between DC2.4 cells and tumor cells than 
between splenocytes and tumor cells, suggesting that 
binding of IL2-GMCSF to DC2.4 cells may be critical to 
initiate specific immune response. During cytotoxicity 
responses, IL2-GMCSF performed multiple roles includ-
ing improved DC phagocytosis, promotion of cell inter-
actions among DCs, tumor cells and effector T cells, as 
well as enhancement of T cell activation, which effectively 
promotes killing efficiency. The cytotoxicity induced 
by IL2-GMCSF corresponded to the promotion of the 
interaction between DC2.4 cells and splenocytes which 
further demonstrates the importance of stimulation on 
DC2.4 cells by IL2-GMCSF. Together, IL2-GMCSF fusion 
cytokine promote diverse anti-tumor immune activities.
The prognosis for patients with advanced melanoma 
remains poor [44]. B16F10 is a malignant melanoma cell 
line expressing IL-2R [45]. In this study, efficient promo-
tion by IL2-GMCSF on immune cell-binding and cyto-
toxicity against B16F10 cells were demonstrated in vitro. 
Accordingly, a mouse melanoma model using B16F10 
cells were established. The in  vivo results demonstrated 
in both immune competent C57BL/6 mice and nude 
mice that the tumor vaccine containing IL2-GMCSF and 
inactivated B16F10 cells (BF group) exerted the most 
remarkably protective effects in terms of both the tumor-
free ratio and the final survival ratio. And tumor regres-
sion in nude mice was also observed in the BF group, 
which is significant than that in the 2CK group. Darrah 
et al. speculated that IL-2 mainly functions to expand the 
activated antigen-specific effector T cells in multifunc-
tional T cells [46], while GM-CSF promotes the cyto-
toxic activity of effector cells in immune responses such 
as antibody-dependent cell-mediated cytotoxicity [47]. 
Vaccination of mice with a poorly immunogenic tumor 
antigen fused to GM-CSF elicited a potent, long-lasting, 
and specific antitumor response [48]. GM-CSF may also 
contribute through its APC chemotactic activity [49]. 
In this study, the IL2-GMCSF fusion cytokine possess-
ing both IL-2 and GM-CSF activities plays distinct roles 
but both activities contribute to effective anti-tumor 
responses. Pre-treatment of the inactivated IL-2R+ 
tumor cells with IL2-GMCSF may provide the highest 
chance for inactivating tumor cells binding with the IL-2 
part of IL2-GMCSF. When the cell-fusion cytokine com-
plexes were injected to tumor region, the GM-CSF part 
of fusion cytokine may interact with DCs in vivo which 
is consistent with the stronger interaction between DCs 
and tumor cells mediated by IL2-GMCSF in vitro. Such 
interaction may tend to activate DCs and enhance the 
tumor antigen presentation which in turn induce spe-
cific anti-tumor cellular immune response at early stage 
and contribute to the inhibition of tumor cell growth. 
And treatment with tumor cell vaccine containing BF 
protected better than tumor cell vaccine prepared with 
the two cytokines (P  <  0.05) which demonstrated that 
BF has advantages over the combinatory application of 
individual cytokines, which may result from the linker 
function that can enhance cell–cell interactions. Inter-
estingly, in this study, the in vivo effects were assessed in 
two types of mice. In the immunocompetent mice, the 
effects showed the activities of all cytotoxic cells, mainly 
should be T lymphocytes. In contrast, in nude mice, the 
main cytotoxic cells should be NK cells, which express 
IL-2 receptor and exert important in tumor exclusion as 
demonstrated in previous report [21]. Thus, the results of 
nude mice actually should reflect the effects of NK cells, 
maybe as well as other types of cytotoxic cells exiting in 
nude mice. These results suggested the full competency 
of IL2-GMCSF to activate anti-tumor cellular immune 
response.
The biological function of IL2-GMCSF protein has 
been reported before. IL2-GMCSF functions as a strong 
anti-tumor factor in mice [33], and significantly acti-
vates NK cells in vitro [50]. IL2-GMCSF has been found 
to activate the JAK/STAT signaling pathway down-
stream of IL-2 and GM-CSF, possibly through some 
special way to combine with their receptors on NK sur-
face. These activities strongly activate NK cells, which 
make up the loss of NK cell function and number due 
to advanced bulky malignancies in vivo. In the present 
study, we focused on another activity of IL2-GMCSF, 
i.e. the bridging effect. This effect can lead to close 
contact of neighboring cells and in turn promotion of 
cell–cell interaction. For the great importance of such 
interaction in immune response, this bridging effect of 
IL2-GMCSF can significantly promote the anti-tumor 
immune response shown in this study and other reports 
[33, 50].
Conclusion
In summary, this study reported a promising future 
for IL2-GMCSF fusion cytokine in the induction and 
enhancement of anti-tumor immune responses which is 
much more effective than either of the two cytokines IL-2 
and GM-CSF alone and could be potentially applied for 
developing novel regimen of anti-tumor therapy. Moreo-
ver, the immune regulatory role of IL2-GMCSF also sup-
port this fusion cytokine is a useful tool to study complex 
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immune response mechanisms, including cytokine activ-
ities on immune cells and the effect of direct or indirect 
interactions among immune cells.
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